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Abstract
Background: Adolescent idiopathic scoliosis (AIS) surgery usually require prolonged operative times with extensive
soft tissue dissection and significant perioperative blood loss, and allogeneic blood products are frequently needed.
Methods to reduce the requirement for transfusion would have a beneficial effect on these patients. Although
many previous studies have revealed the efficacy of tranexamic acid (TXA) in spinal surgery, there is still a lack of
agreement concerning the reduction of both blood loss and transfusion requirements of large dose tranexamic
acid (TXA) in surgery for adolescent idiopathic scoliosis (AIS). The objective of this study was to elevate the efficacy
and safety of a large dose tranexamic acid (TXA) in reducing transfusion requirements of allogeneic blood products
in adolescent idiopathic scoliosis (AIS) surgery using a retrospective study designed with historical control group.
Methods: One hundred thirty seven consecutive AIS patients who underwent surgery treatment with posterior
spinal pedicle systems from August 2011 to March 2015 in our scoliosis center were retrospectively reviewed.
Patients were divided into two groups, the TXA group and the historical recruited no TXA group (NTXA).
Preoperative demographics, radiographic parameters, operative parameters, estimated blood loss (EBL), total
irrigation fluid, number of patients requiring blood transfusion, mean drop of Hb (Pre-op Hb-Post-op Hb),
haematocrit pre and post-surgery, mean volume of blood transfusion, hospitalization time, and adverse effect were
recorded and compared.
Results: All the patients were successfully treated with satisfied clinical and radiographic outcomes. There were 71
patients in the TXA group and 66 patients in the NTXA group. The preoperative demographics were homogeneity
between two groups (P > 0.05). There were no significant difference in average operative time between two groups
(209 min vs 215 min, p >0.05). Number of patients in the TXA group showed a significant decrease in transfusion
requirements with an associated reduced intraoperative blood loss of nearly 45% compared with those in NTXA
group (8 vs37, 619 ml vs 1125 ml, P < 0.05). There were no significant difference in total irrigation fluid between
two groups (540 vs 550, p >0.05). Additional, patients in NTXA group showed significant decrease of Hb compared
with patients in TXA group (5.2 g/dL vs 3.3 g/dL, P < 0.05), No significant difference were found in hospitalization
time between two groups (6.3vs7.2 days, P > 0.05). No minor adverse effects associated with use of TXA were
noted.
Conclusions: Use of large dose tranexamic acid routinely seems to be effective and safe in reducing allogenic
blood transfusion and blood loss in adolescent idiopathic scoliosis surgery.
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Background
Tranexamic acid (TXA) is a kind of synthetic antifibri-
nolytic which can inhibit both fibrinolysis and the activa-
tion of plasminogen by plasminogen activator to delay
fibrinolysis and stop bleeding [1–3]. Its effectiveness in
reducing postoperative blood loss and minimizing trans-
fusions has been documented in various surgical subspe-
cialties including cardiac, transplant, and orthopaedic
surgery [4, 5]. The effectiveness of antifibrinolytic drugs
has been demonstrated in reducing blood loss and the
amount of blood transfused in children undergoing
scoliosis surgery [6–8], and some current studies also
showed efficacy of TXA in reducing allogeneic blood
products transfusion in AIS surgery [8–10]. We tried to
provide evidence in the form of a historical control study
to access efficacy and safety of large dose tranexamic
acid in reducing allogeneic blood products in adolescent
idiopathic scoliosis surgery.
Methods
From August 2011 to March 2015, 137 consecutive pa-
tients diagnosed with AIS underwent surgery were retro-
spectively reviewed. Since July 2013, all patients with
AIS had received large dose TXA during surgery at our
institution. The 71 patients who received intraoperative
TXA were categorized as the TXA group. The historical
control group (no TXA group) consisted of the remain-
ning 66 AIS patients who underwent surgery without be-
ing given TXA. All patients were screened for renal
insufficiency and coagulopathy before surgery. Correc-
tion of AIS were performed by posterior full pedicle sys-
tem using the same surgical technique under monitoring
of combined MEPs and SEPs, and all surgeries were per-
formed by the same senior doctor. Cell salvage autolo-
gous blood recovery system was used in all cases. No
preoperative blood donation was obtained from all pa-
tients. Outcome measures including preoperative demo-
graphics (age, sex, BMI, ASA physical status, properative
values of haemoglobin and haematocrit), radiographic
parameters (preoperative Cobb angle, postoperative
Cobb angle, coronal balance, correction rate), operative
data (operative time, mean BP, number of levels fused,
screw density), estimated blood loss(EBL), total irrigation
fluid, number of patients requiring blood transfusion,
drop of Hb (Pre-op Hb-Post-op Hb), mean volume of
blood transfusion, hospitalization time, and adverse ef-
fects were recorded and compared. The standard TXA
dose used in our study was 100 mg/kg intravenously
over 15 min after induction of anesthesia and before in-
cision followed by an infusion of 10 mg/kg per hour dur-
ing surgery until skin closure. Indications for blood
transfusion during operation including significant drop
in systolic blood pressure (<50 mmHg), any perceived
rapid loss of blood, decreased urine output, and
alterations in the spinal cord monitoring responses
which were decided by the surgeon and anesthetist.
After surgery, patients in both groups were managed in
the same manner. No suction drain was used in all the
patients. Haemoglobin (Hb)/haematocrit(Hct) were rou-
tinely checked 1 day after operation. Patients with
haemoglobin levels <7 g/dL were considered for transfu-
sion, and patients with haemoglobin levels >7 g/dL
showed clinical symptoms including dizziness, excessive
fatigue, and hypotension in the case of rule out other
posssible causes were also considered as indications for
transfusion. No changes were made in the indications
for transfusion and hemostatic techniques over the study
period. The study has been approved by the Institutional
Ethics Committee and informed written consent was ob-
tained from all participants.
Screw density was defined as the total number of
screws inserted divided by the total number of level
fused.
The coronal spinal balance in the frontal plane was de-
termined on standing radiograph by measuring the C7
plumb line distance from the center sacral line.
Estimated blood volume was calculated using a for-
mula described by Nadler et al. [11]. EBL was calculated
by adding the blood volume collected by both the suc-
tion and cell-saver (CS) system and by weighing the sur-
gical sponges.
The total irrigation fluid was measured strictly by the
nurses prior to use in the operative field.
Statistical analysis
Descriptive statistics were analyzed by SPSS17.0. Stu-
dent’s t-test was used to compare continuous variables,
and a two-sample z test was used to compare sample
proportions. Results were considered statistically signifi-
cant with a p value less than 0.05.
Results
All the 137 AIS patients were successfully reviewed.
There were 71 patients in the TXA group and 66 pa-
tients in the NTXA group. All patients showed normal
blood urea nitrogen, blood creatinine level, bleeding
time, prothrombin time, activated partial thrombin time,
international normalized ratio, and serum platelet con-
centration preoperative. No patient sustained any major
intra- or postoperative complications in either group. All
patients received general anesthesia with a goal mean ar-
terial pressure of 60 to 70 mmHG and epidural catheters
for postoperative pain management. There were no sig-
nificant differences in the demographics of patients in
the two groups (age, sex, BMI, ASA physical status, pre-
operative values of Hb/Hct, preoperative Cobb angle,
postoperative Cobb angle, correction rate, coronal bal-
ance, number of levels fused, screw density) (Table 1).
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The mean surgical time was 209 min in the TXA group
and 215 min in the NTXA group (P >0.05). Patients in
the TXA group showed a significant decrease in transfu-
sion requirements with an associated reduced intraoper-
ative blood loss of nearly 45%compared with those in
NTXA group (8vs37, 619 ml vs1125 ml, P < 0.05).
There were no significant difference in total irrigation
fluid between two groups (540 ml vs 550 ml, p >0.05).
Additional, patients need blood transfusion in NTXA
group showed significant decrease of Hb compared
with those in tranexamic acid group (5.2 g/dL vs 3.3 g/
dL, P < 0.05).No significant difference were found in
hospitalization time between two groups (6.3 vs
7.2 days, P > 0.05) (Table 2). A total of 45 patients need
blood transfusion, 8 in the TXA group and 37 in the
NTXA group, no statistically significant differences
were showed between the recorded parameters of these
patiens (P > 0.05, Table 3). No minor adverse effects,
such as headache, nausea, vomiting, or diarrhea, associ-
ated with the use of TXA were noted.
Discussion
Tranexamic Acid (TXA) is a synthetic lysine-analogue
antifibrinolytic that was first patented in 1957 [12]. The
mechanism of action is the competitive blockade of the
lysine-binding sites of plasminogen, plasmin, and tissue
plasminogen activator [13]. Use of TXA can reduce
blood loss in cardiac surgery, trauma, liver surgery and
solid organ transplantation and non-surgical diseases
were demonstrated [14, 15]. In a recent meta-analysis of
over 100 RCTs that compared TXA vs no TXA or a pla-
cebo in more than 10,000 patients undergoing surgery
showed overwhelming evidence that TXA reduces the
probability of transfusion by 38 % [16]. However, There
are few RCTs on TXA use in pediatric scoliosis surgery.
The safety and efficacy of TXA for spinal scoliosis sur-
gery are still controversial.
Faraoni et al. [17] concluded that in pediatric spine
surgery (mainly scoliosis correction), TXA did decrease
blood loss and transfusion requirements. Yang et al. [18]
conducted a meta-analysis of intravenous TXA use (n =
581) in spinal surgery compared to pediatric scoliosis
surgery showed a reduction in postoperative blood loss
by 389.21 mL and the amount of blood transfused by
134.55 mL with TXA. Elwatidy et al. [19] reported a sig-
nificant reduction in EBL in patients who were adminis-
tered TXA during spinal surgery, whereas Baldus et al.
[20] reported no advantage of TXA administration for
blood loss during spinal surgery. Dhawale et al. [21] de-
termined that aminocaproic acid resulted in similar EBL
to patients who had no AF in a population of pediatric
patients with scoliosis secondary to cerebral palsy. A
total of 137 AIS patients were retrospectively enrolled in
our study, of which 45 patients need blood transfusion,
8 in the TXA group and 37 in the NTXA group. Patients
in the TXA group showed a significant decrease in
transfusion requirements with an associated reduced in-
traoperative blood loss of nearly 45%compared with
those in NTXA group (8vs37, 619 ml vs1125 ml, P <
0.05). Additional, patients need blood transfusion in
NTXA group showed significant decrease of Hb/Hct
compared with those in tranexamic acid group (5.2 g/dL
vs 3.3 g/dL, P < 0.05).No significant difference were






Age (ys) 15.5 16.2 >0.05
Sex (F/M) (49/22) (45/21) >0.05
BMI 17.1 16.9 >0.05
ASA I I >0.05
Pre-op Cobb angle(°) 65.5 62.4 >0.05
Post-op Cobb angle(°) 17.6 18.1 >0.05
Magnitude of correction (%) 72.8 71.6 >0.05
Number of levels fused 13.1 12.8 >0.05
Pedicle screw density (%) 81 79.7 >0.05
Pre-op coronal balance(mm) 12.3 12.9 >0.05
Post-op coronal balance(mm) 4.6 4.8 >0.05
Pre-op Hb (g/dL) 13.2 13.4 >0.05
Pre-op Hct (%) 43.6 42.9 >0.05






Mean BP (mm Hg) 66.4 68.2 >0.05
Blood transfusion (number) 8 37 <0.05
Estimated blood loss (mL) 619 1125 <0.05
Hb drop (g/dL) 3.3 5.2 <0.05
Operative time (min) 209 215 >0.05
Hospitalization time (days) 6.3 7.2 >0.05
The total irrigation fluid 540 550 >0.05
Post-op Hct (%) 33.1 % 27.8 % <0.05







Mean BP (mm Hg) 66.7 67.2 >0.05
Blood transfusion (ml) 373 384 >0.05
Estimated blood loss (mL) 1425 1470 >0.05
Hb drop (g/dL) 6.9 7.3 >0.05
Operative time (min) 215 213 >0.05
Hospitalization time (days) 7.4 7.9 >0.05
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found in hospitalization time between two groups (6.3 vs
7.2 days, P > 0.05) (Table 2).
A wide range of TXA dosing has been advocated,
depending on the indication. Most studies use intra-
venous TXA. The bolus and infusion dosing vary, but
pharmacokinetic evidence would suggest the use of a
10 to 15 mg/kg loading dose, followed by an infusion
dose of 1 mg/kg/h or repeated bolus dosing [13, 22].
It is now clear from current literature that moderate
to high doses of TXA in cardiac surgery are associ-
ated with an increased risk of seizures [23, 24]. There
is currently no clinical evidence that the use of TXA
increases the risk of thromboembolic events, namely
myocardial infarction, stroke, deep vein thrombosis or
pulmonary embolism according to meta-analyses and
clinical trials cited in the trauma and orthopedic [2,
25, 26] settings. In our study, TXA dose 100 mg/kg
intravenously over 15 min after induction of
anesthesia and before incision followed by an infusion
of 10 mg/kg per hour during surgery until skin clos-
ure was used as a standard protocol in the TXA
group. No minor adverse effects, such as headache,
nausea, vomiting, or diarrhea, associated with the use
of TXA were noted.
A recent retrospective study of 36,901 patients under-
going elective spinal surgery found that those who re-
ceived transfusions, even a single unit, had increased
length of stay and postoperative morbidity [27]. Dhawale
et al. [21] determined that TXA was more effective in
reducing blood loss in cerebral palsy patients who
underwent scoliosis correction than AFs and EACA, and
no significant difference were found between the TXA
group and no TXA group in length of hospital stay. In
our study, postoperative length of stay was decreased in
the group who received TXA, but no statistically signifi-
cant difference were found between two groups which
might due to the sample size and other procedures
performed postoperatively. However, it is likely that the
reduction in transfusion rates trend to reducing
hospitalization time and morbidities with associated im-
provements in patient outcomes.
Ialenti et al. [28] reported that prolonged operative
time is associated with increased blood loss. Mark J
et al. [29] reported that The use of tranexamic acid has
also led to a statistically significant reduction in oper-
ation time (188 vs 223 min). Frederic et al. [30] reported
that the length of surgery, in minutes, was not signifi-
cantly different between the non-TXA and TXA pa-
tients. There were no significant difference between two
groups in operative time in this study. We think a bipo-
lar sealer played an important role in assisting
hemostasis which might result in shorten operative
time, and this is familiar to the former study performed
by Mankin [31].
The limitations of this study are inherent to its retro-
spective designed with historical control group. Another
potential limitation was the indications for transfusion
were not defined with objective parameters.
Conclusion
Our retrospective study designed with historical control
group showed that large dose TXA seems to be effective
and safe in reducing allogenic blood transfusion and
blood loss in adolescent idiopathic scoliosis surgery.
Prophylactic TXA may provide a worthwhile reduction
of excessive blood loss and decrease the need for blood
transfusion during idiopathic scoliosis surgery in adoles-
cent patients.
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